HRs for outcomes with aspirin treatment compared with no aspirin treatment at Cox regression, by gender in 18 646 patients with type 2 diabetes followed for 4 years
| Patients N | Events N (%) | Events/1000 person-years | HR* (95% CI) | p Value | |
|---|---|---|---|---|---|
| Non-fatal/fatal CVD | |||||
| Women | 8341 | 349 (4.2) | 11.8 | 1.28 (1.01 to 1.61) | 0.04 |
| Men | 10305 | 654 (6.4) | 18.2 | 0.98 (0.82 to 1.17) | 0.8 |
| Fatal CVD | |||||
| Women | 8341 | 65 (0.8) | 2.2 | 1.22 (0.73 to 2.06) | 0.6 |
| Men | 10305 | 140 (1.4) | 3.8 | 0.70 (0.48 to 1.04) | 0.08 |
| Non-fatal/fatal CHD | |||||
| Women | 8341 | 231 (2.8) | 7.8 | 1.41 (1.07 to 1.87) | 0.02 |
| Men | 10305 | 467 (4.5) | 12.9 | 1.09 (0.89 to 1.35) | 0.4 |
| Fatal CHD | |||||
| Women | 8341 | 54 (0.7) | 1.8 | 1.09 (0.61 to 1.93) | 0.7 |
| Men | 10305 | 122 (1.2) | 3.3 | 0.69 (0.45 to 1.05) | 0.08 |
| Non-fatal/fatal stroke | |||||
| Women | 8341 | 128 (1.5) | 4.3 | 1.02 (0.68 to 1.52) | 0.9 |
| Men | 10305 | 210 (2.0) | 5.8 | 0.85 (0.62 to 1.16) | 0.3 |
| Fatal stroke | |||||
| Women | 8341 | 12 (0.1) | 0.4 | 1.71 (0.51 to 5.69) | 0.7 |
| Men | 10305 | 21 (0.2) | 0.6 | 1.02 (0.41 to 2.55) | 0.9 |
| Total mortality | |||||
| Women | 8341 | 249 (3.0) | 8.3 | 1.07 (0.81 to 1.40) | 0.6 |
| Men | 10305 | 406 (3.9) | 11.1 | 0.81 (0.64 to 1.02) | 0.07 |
*Adjusted by stratification with deciles of a propensity score including the covariates age, diabetes duration, previous hospitalisation, type of hypoglycaemic treatment, HbA1c, smoking, BMI, systolic blood pressure, ratio total-to-HDL cholesterol, albuminuria >20 µg/min, antihypertensive drugs, statins, other lipid lowering drugs, oestrogen and multidose dispensation. HbA1c was also added as covariate.
BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein.